Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.japh.2022.03.008 | DOI Listing |
JAMA Ophthalmol
December 2023
Department of Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Clin Drug Investig
March 2023
Rocky Mountain Poison and Drug Safety, Denver Health and Hospital Authority, 1391 Speer Blvd UNIT 600, Denver, CO, 80204, USA.
Background And Objective: While the current landscape of opioid use disorder (OUD) is complicated by the increase in use of non-prescription opioids, prescription opioids continue to be frequently used in non-medical ways. In response to this abuse, pharmaceutical companies have developed abuse deterrent formulations (ADFs) for extended-release (ER) opioids. To test the effectiveness of Xtampza ER ADF (oxycodone myristate) at reducing tampering, its rate of tampering in a treatment-center population was compared to immediate release (IR) single entity (SE) oxycodone, other ER oxycodone opioids, and ER oxymorphone.
View Article and Find Full Text PDFJ Am Pharm Assoc (2003)
July 2022
Professor of Oral Surgery and Pharmacology, University of Pennsylvania School of Dental Medicine, Philadelphia, PA.
Objective: To assess the association between long term prescription opioid treatment medically dispensed for non-cancer pain and the initiation of injection drug use (IDU) among individuals without a history of substance use.
Design: Retrospective cohort study.
Setting: Large administrative data source (containing information for about 1.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!